Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? - Wikidata - wikimedia - TriplyDB

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

http://www.wikidata.org/entity/Q42408046

about

Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials.Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology.Combined modality treatments in pancreatic cancer.Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.

P2860

Q34896914-A52A0259-ADE2-40B4-AC61-614097B10AD3 Q35190260-C35D102F-763C-47FE-BE4B-644A6DF27DA9 Q37342746-91ADC3A0-4EFD-4F55-BCC8-9D0EB0072BAC Q37996462-450C2CEE-CB4D-4DB5-8A4B-F334D5199B38 Q40165790-91F9BF8A-F8DE-4303-AADA-249501C521C9 Q51799016-B75E2C30-2732-4187-9A5B-7BE334C91220

P2860

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

http://www.wikidata.org/entity/Q42408046

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@en

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@nl

type

label

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@en

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@nl

prefLabel

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@en

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@nl

P1433

Q42408046-D742DF65-3C76-432E-B279-7CE4DA36A1BE

P1476

Q42408046-A597EAB2-DB17-4C93-BC32-BF1D569CB5BF

P2093

Q42408046-40F0D97B-FB01-4319-8414-8EA45E1C7509

P2860

Q42408046-02B59A5E-250F-4B6A-9503-7D324CE3534D

Q42408046-040CE5D4-C376-4547-B000-C53E35FC57DA

Q42408046-1AC42720-5949-4D0D-AA3E-2BCFC7ABE148

Q42408046-1F7B2AC4-7D50-400A-A7A2-E6B806EC9494

Q42408046-2822E34C-CB67-47B6-A7B2-0E1C565D7B38

Q42408046-39BD229A-49A1-48C2-8C9B-D547E8ED26C0

Q42408046-3AAD76B2-AF47-4E0F-94B8-486720DF3FC9

Q42408046-3AB11210-05F2-443A-8C64-77FEE5854B9D

Q42408046-3CE3ED1F-C48C-492E-B4D8-3C6A4D236A68

Q42408046-52003655-330C-42C0-9C63-DBB5AC430B14

P304

Q42408046-C0033137-B92F-4982-B5DA-219955262888

P31

Q42408046-2DAA83B0-2C75-45A0-A7FE-4919B1856BE4

Q42408046-73c627cd-eb1a-4533-889b-1ea33545b0e0

P356

Q42408046-06B0FEE9-4F77-47E9-BDB3-7B2D3119AAEA

P407

Q42408046-B5D5A8C8-70A9-4EBF-B76F-6B565E2A6B17

P433

Q42408046-D9DAB86E-A860-4157-836F-62A6A694125B

P478

Q42408046-EC1E1545-6123-4E24-A914-67CA5AF9496E

P577

Q42408046-E2D5D8A3-F0AB-4598-BA99-68A8CC163AB7

P5875

Q42408046-DCB09B61-9F22-4F86-A3BC-A6D7715928C4

P698

Q42408046-5F2359F6-A95E-4BFB-9F8F-B86F85704ABC

P932

Q42408046-01CB4F6D-B62C-4F45-A4DB-FCA96105F676

P356

WJG.V16.I39.4883

P1433

World Journal of Gastroenterology

P1476

Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?

@en

P2093

Michele Reni

http://www.w3.org/2001/XMLSchema#string

P2860

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.

Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.

P304

4883-4887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V16.I39.4883

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47451501

http://www.w3.org/2001/XMLSchema#string

P698

20954273

http://www.w3.org/2001/XMLSchema#string

P932

2957595

http://www.w3.org/2001/XMLSchema#string